# Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

> **NCT00209677** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Hokkaido Gastrointestinal Cancer Study Group** · enrollment: 40 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT00209677
- **Lead sponsor:** Hokkaido Gastrointestinal Cancer Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2007-12
- **Target enrollment:** 40 (ESTIMATED)
- **Why stopped:** Unfortunately, other Phase III clinical Study (GEM+S-1 vs GEM vs S-1) have been started in Japan.

h
- **Last updated:** 2007-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00209677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00209677, "Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00209677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*